Contributions
Abstract: EP1635
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Multiple sclerosis (MS) first-line disease-modifying drug (DMD) treatment options now include oral drugs in addition to injectable therapies. Purpose of this multicenter real-life prospective study was to assess the proportion of patients discontinuing a newly initiated first-line treatment, for any reason, during a one-year follow-up period.
Nine MS centres in Emilia-Romagna, Italy, enrolled consecutive MS patients starting any first-line DMD during 2015, and recorded data on treatment discontinuation throughout a one-year period.
Five-hundred patients were enrolled in the study (353F, 147M; mean age: 43 years; mean baseline EDSS: 1.8 +/- 1.3), and followed up for at least one year or until the DMD was discontinued (mean: 13 +/-5 months). An injectable drug (beta-interferon 1a/b, glatiramer acetate) was started in 246 patients (49%) and an oral one (dimethylfumarate, teriflunomide) in 254 (51%); 155 (31%) were treatment-naïve. A total of 113 (23%) patients discontinued the drug, mostly due to adverse events/tolerability issues (54% of cases) or ongoing disease activity (33%). There was no difference in a) the proportion of patients on oral or injectable DMD discontinuing treatment (22% and 24%, respectively), b) the reason for treatment discontinuation, and c) in the time to treatment discontinuation between the two groups. Patients starting oral drugs had higher basal EDSS values (2.1 versus 1.5, p< 0.001), as had treatment-naïve patients (1.9 versus 1.6; p=0.02). Treatment-naïve patients started injectable therapies, as opposed to oral drugs, more frequently (117/155 versus 129/345; p< 0.001), and were more likely to discontinue treatment (45/155 versus 68/345, p=0.02).
There was no difference in the acceptability of injectable versus oral first-line DMD in MS patients, as measured by the proportion of patients discontinuing the drug for any reason during the first year of treatment.
Disclosure:
Franco Granella has received research grants for his Institution from Biogen; has served on scientific advisory boards for Biogen, Novartis, Sanofi Genzyme and Merck Serono; has received funding for travel from Biogen, Merck Serono and Sanofi Genzyme
Erica Curti has served on scientific advisory boards for Merck Serono; has received funding for travel from Biogen, Merck Serono, Novartis and Sanofi Genzyme;.
Diana Ferraro has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Patrizia Sola has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Anna Maria Simone has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Enrico Montanari has received funds and/or travel grants from Teva, Biogen, Merck Serono, Novartis
Susanna Malagù has served on advisory boards and/or received travel grants from Bayer, Biogen and Sanofi-Genzyme.
Valentina Camera has nothing to disclose.
Eleonora Baldi has nothing to disclose.
Veria Vacchiano has nothing to disclose.
Angelica Guareschi has nothing to disclose.
Sara Montepietra has nothing to disclose.
Silvia Strumia has nothing to disclose.
Mario Santangelo has nothing to disclose.
Luisa Caniatti has nothing to disclose.
Alessandra Lugaresi has nothing to disclose.
Ilaria Pesci has nothing to disclose.
Luisa Motti has nothing to disclose.
Walter Neri has nothing to disclose.
Paolo Immovilli has nothing to disclose.
Abstract: EP1635
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Multiple sclerosis (MS) first-line disease-modifying drug (DMD) treatment options now include oral drugs in addition to injectable therapies. Purpose of this multicenter real-life prospective study was to assess the proportion of patients discontinuing a newly initiated first-line treatment, for any reason, during a one-year follow-up period.
Nine MS centres in Emilia-Romagna, Italy, enrolled consecutive MS patients starting any first-line DMD during 2015, and recorded data on treatment discontinuation throughout a one-year period.
Five-hundred patients were enrolled in the study (353F, 147M; mean age: 43 years; mean baseline EDSS: 1.8 +/- 1.3), and followed up for at least one year or until the DMD was discontinued (mean: 13 +/-5 months). An injectable drug (beta-interferon 1a/b, glatiramer acetate) was started in 246 patients (49%) and an oral one (dimethylfumarate, teriflunomide) in 254 (51%); 155 (31%) were treatment-naïve. A total of 113 (23%) patients discontinued the drug, mostly due to adverse events/tolerability issues (54% of cases) or ongoing disease activity (33%). There was no difference in a) the proportion of patients on oral or injectable DMD discontinuing treatment (22% and 24%, respectively), b) the reason for treatment discontinuation, and c) in the time to treatment discontinuation between the two groups. Patients starting oral drugs had higher basal EDSS values (2.1 versus 1.5, p< 0.001), as had treatment-naïve patients (1.9 versus 1.6; p=0.02). Treatment-naïve patients started injectable therapies, as opposed to oral drugs, more frequently (117/155 versus 129/345; p< 0.001), and were more likely to discontinue treatment (45/155 versus 68/345, p=0.02).
There was no difference in the acceptability of injectable versus oral first-line DMD in MS patients, as measured by the proportion of patients discontinuing the drug for any reason during the first year of treatment.
Disclosure:
Franco Granella has received research grants for his Institution from Biogen; has served on scientific advisory boards for Biogen, Novartis, Sanofi Genzyme and Merck Serono; has received funding for travel from Biogen, Merck Serono and Sanofi Genzyme
Erica Curti has served on scientific advisory boards for Merck Serono; has received funding for travel from Biogen, Merck Serono, Novartis and Sanofi Genzyme;.
Diana Ferraro has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Patrizia Sola has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Anna Maria Simone has received travel grants and/or speaker honoraria from Merck Serono, Biogen, Novartis, TEVA and Sanofi-Genzyme.
Enrico Montanari has received funds and/or travel grants from Teva, Biogen, Merck Serono, Novartis
Susanna Malagù has served on advisory boards and/or received travel grants from Bayer, Biogen and Sanofi-Genzyme.
Valentina Camera has nothing to disclose.
Eleonora Baldi has nothing to disclose.
Veria Vacchiano has nothing to disclose.
Angelica Guareschi has nothing to disclose.
Sara Montepietra has nothing to disclose.
Silvia Strumia has nothing to disclose.
Mario Santangelo has nothing to disclose.
Luisa Caniatti has nothing to disclose.
Alessandra Lugaresi has nothing to disclose.
Ilaria Pesci has nothing to disclose.
Luisa Motti has nothing to disclose.
Walter Neri has nothing to disclose.
Paolo Immovilli has nothing to disclose.